Frequently Asked Questions
About Dosing

Do all the dosing schedules still give me steady-state levels?

Yes, regardless of which dosing schedule you and your healthcare provider choose, as long as you follow the schedule regularly, Hizentra delivers steady-state levels.* It is important that your healthcare provider monitor your serum IgG levels and clinical response to treatment.

*Based on pharmacokinetic modeling and simulations

How does the volume of a biweekly (every 2 weeks) infusion compare to that of weekly?

The volume of Hizentra 20% infused every 2 weeks is double that of the volume of Hizentra 20% infused weekly. If you have been using a 10% SCIg product weekly, the volume of Hizentra 20% biweekly will be the same as what you have been receiving.* Talk to your healthcare provider about how to adjust your infusion routine.

*Based on an equivalent dose in grams

How does the volume of a more frequent (eg, daily) infusion compare to that of weekly?

The volume of Hizentra 20% infused frequently (eg, every day or every few days) will depend on the schedule you and your healthcare provider choose. However, the volume of Hizentra 20% solution will still be less than the volume of a 10% solution for an equivalent dose.*

*Based on an equivalent dose in grams

Does it take longer to infuse a biweekly (every 2 weeks) dose than a weekly dose? Does it take less time to infuse a dose more frequently (eg, every day or every few days)?

Your experience may vary depending on a number of factors, including number of infusion sites, infusion rate, tubing, and how well you tolerate the treatment. Talk with your healthcare provider about what is best for you.

Can I switch from IVIg to any of the possible Hizentra dosing schedules?

Yes, it is possible to switch from IVIg therapy to Hizentra, on any of the possible dosing schedules. Talk with your healthcare provider about which option is best for you.




Your Tools for Administering Hizentra

At CSL Behring, we recognize that self-infusion of Ig therapy may be a new experience for healthcare professionals as well as their patients. Next find helpful information and tools on the dosing and administration of Hizentra.

Important Safety Information
Expand

Important Safety Information

WARNING: Thrombosis (blood clotting) can occur with immune globulin products, including Hizentra. Risk factors can include: advanced age, prolonged immobilization, a history of blood clotting or hyperviscosity (blood thickness), use of estrogens, installed vascular catheters, and cardiovascular risk factors.

If you are at high risk of thrombosis, your doctor will prescribe Hizentra at the minimum dose and infusion rate practicable and will monitor you for signs of thrombosis and hyperviscosity. Always drink sufficient fluids before administration.

Immune Globulin Subcutaneous (Human), Hizentra®, treats various forms of primary immunodeficiency (PI) in patients age 2 and over.

Tell your doctor if you have had a serious reaction to other immune globulin medicines or have been told you also have a deficiency of the immunoglobulin called IgA, as you might not be able to take Hizentra. You should not take Hizentra if you know you have hyperprolinemia (too much proline in your blood).

Infuse Hizentra under your skin only; do not inject into a blood vessel.

Allergic reactions can occur with Hizentra. If your doctor suspects you are having a bad allergic reaction or are going into shock, treatment will be discontinued. Immediately tell your doctor or go to the emergency room if you have signs of such a reaction, including hives, trouble breathing, wheezing, dizziness, or fainting.

Tell your doctor about any side effects that concern you. Immediately report symptoms that could indicate a blood clot, including pain and/or swelling of an arm or leg, with warmth over affected area; discoloration in arm or leg; unexplained shortness of breath; chest pain or discomfort that worsens with deep breathing; unexplained rapid pulse; and numbness or weakness on one side of the body. Your doctor will also monitor symptoms that could indicate hemolysis (destruction of red blood cells), and other potentially serious reactions that have been seen with Ig treatment, including aseptic meningitis syndrome (brain swelling); kidney problems; and transfusion-related acute lung injury.

The most common drug-related adverse reactions in the clinical trial for Hizentra were swelling, pain, redness, heat or itching at the site of injection; headache; back pain; diarrhea; tiredness; cough; rash; itching; nausea and vomiting.

Hizentra is made from components of human blood. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Before being treated with Hizentra, inform your doctor if you are pregnant, nursing or plan to become pregnant. Vaccines (such as measles, mumps and rubella) might not work well if you are using Hizentra. Before receiving any vaccine, tell the healthcare professional you are being treated with Hizentra.

Please see full prescribing information for Hizentra, including boxed warning and the patient product information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Collapse
CSL Behring
Hizentra is manufactured by CSL Behring AG and distributed by CSL Behring LLC.
Hizentra® is a registered trademark of CSL Behring AG.
© 2018 CSL Behring LLC. The product information presented on this site is intended for US residents only. HIZ/09-12-0016k(1) 9/2015